Design and characterization of paclitaxel-verapamil co-encapsulated PLGA nanoparticles: Potential system for overcoming P-glycoprotein mediated MDR

Thorgeirsson, 2002, Molecular pathogenesis of human hepatocellular carcinoma, Nat. Genet., 31, 339, 10.1038/ng0802-339 Housman, 2014, Drug resistance in cancer: an overview, Cancers, 6, 1769, 10.3390/cancers6031769 Zahreddine, 2013, Mechanisms and insights into drug resistance in cancer, Front. Pharmacol., 4, 28, 10.3389/fphar.2013.00028 Wu, 2014, Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches, Cancer Lett., 347, 159, 10.1016/j.canlet.2014.03.013 Nieth, 2003, Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi), FEBS Lett., 545, 144, 10.1016/S0014-5793(03)00523-4 Maxwell, 2013, Non-Hodgkin’s B-cell lymphoma: advances in molecular strategies targeting drug resistance, Exp. Biol. Med., 238, 971, 10.1177/1535370213498985 Kapse-Mistry, 2014, Nanodrug delivery in reversing multidrug resistance in cancer cells, Front. Pharmacol., 5, 159 Ahmed, 2012, Theranostic applications of nanoparticles in cancer, Drug Discov. Today, 17, 928, 10.1016/j.drudis.2012.03.010 Wang, 2012, Nanoparticle delivery of cancer drugs, Annu. Rev. Med., 63, 185, 10.1146/annurev-med-040210-162544 Tang, 2010, Recent progress in nanotechnology for cancer therapy, Chin. J. Cancer, 29, 775, 10.5732/cjc.010.10075 Kumari, 2010, Biodegradable polymeric nanoparticles based drug delivery systems, Colloids Surface. B Biointerfaces, 75, 1, 10.1016/j.colsurfb.2009.09.001 Yang, 2009, Development of highly porous large PLGA microparticles for pulmonary drug delivery, Biomaterials, 30, 1947, 10.1016/j.biomaterials.2008.12.044 Kerimoğlu, 2012, Poly (lactic-co-glycolic acid) based drug delivery devices for tissue engineering and regenerative medicine, Ankem Derg., 26, 86, 10.5222/ankem.2012.086 Acharya, 2011, PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect, Adv. Drug Deliv. Rev., 63, 170, 10.1016/j.addr.2010.10.008 Alipour, 2015, Inhalable, large porous PLGA microparticles loaded with paclitaxel: preparation, in vitro and in vivo characterization, J. Microencapsul., 32, 661, 10.3109/02652048.2014.944949 Danhier, 2009, Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel, J. Control. release, 140, 166, 10.1016/j.jconrel.2009.08.011 Baek, 2015, Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles, Int. J. Pharm., 478, 617, 10.1016/j.ijpharm.2014.12.018 Panchagnula, 1998, Pharmaceutical aspects of paclitaxel, Int. J. Pharm., 172, 1, 10.1016/S0378-5173(98)00188-4 Arıca Yegin, 2006, Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification, Drug Dev. Ind. Pharm., 32, 1089, 10.1080/03639040600683501 Veltkamp, 2006, A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer, Br. J. cancer, 95, 729, 10.1038/sj.bjc.6603312 Alipour, 2016, Non-invasive endotracheal delivery of paclitaxel-loaded alginate microparticles, J. Chemother., 28, 411, 10.1080/1120009X.2015.1105624 Thomas, 2003, Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein, Cancer control.., 10, 159, 10.1177/107327480301000207 Dorr, 1994, Pharmacology and toxicology of Cremophor EL diluent, Ann. Pharmacother., 28, S11, 10.1177/10600280940280S503 Yu, 2013, Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?, Cancer Metastasis Rev., 32, 211, 10.1007/s10555-012-9402-8 Varma, 2003, P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement, Pharmacol. Res., 48, 347, 10.1016/S1043-6618(03)00158-0 Wang, 2011, Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance, Biomaterials, 32, 9444, 10.1016/j.biomaterials.2011.08.041 Wang, 2005, In vitro cytotoxicity of stealth liposomes Co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells, Biol. Pharm. Bull., 28, 822, 10.1248/bpb.28.822 Niu, 2010, In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells, J. Drug Target, 18, 468, 10.3109/10611860903508804 Song, 2008, PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: Systematic study of particle size and drug entrapment efficiency, Int. J. Pharm., 350, 320, 10.1016/j.ijpharm.2007.08.034 Naik, 2012, Development of sustained release micro/nanoparticles using different solvent emulsification technique: a review, Int. J. Pharm. Bio Sci., 3, 573 Trickler, 2008, A novel nanoparticle formulation for sustained paclitaxel delivery, AAPS PharmSciTech, 9, 486, 10.1208/s12249-008-9063-7 Metri, 2013, Ayurveda for chemo-radiotherapy induced side effects in cancer patients, J. stem cells, 8, 115 Chen, 2013, Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics, Int. J. Nanomedicine, 8, 2677, 10.2147/IJN.S45429 Bhardwaj, 2009, PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat, Pharm. Res., 26, 2495, 10.1007/s11095-009-9965-4 Qin, 2014, Overcoming cancer multidrug resistance by codelivery of doxorubicin and verapamil with hydrogel nanoparticles, Macromol. Biosci., 14, 1106, 10.1002/mabi.201400035 Danhier, 2009, Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation, J. Control. release, 133, 11, 10.1016/j.jconrel.2008.09.086 Arya, 2015, Poly (d, l-lactide-co-glycolide)–chitosan composite particles for the treatment of lung cancer, Int. J. Nanomedicine, 10, 2997 Man, 2015, Oleanolic acid-loaded PEGylated PLA and PLGA nanoparticles with enhanced cytotoxic activity against cancer cells, Mol. Pharm., 12, 2112, 10.1021/acs.molpharmaceut.5b00085 Mu, 2003, A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS, J. Control. Release, 86, 33, 10.1016/S0168-3659(02)00320-6 Jin, 2009, Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells, Pharm. Res., 26, 1776, 10.1007/s11095-009-9889-z Mo, 2005, Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate, J. Control. Release, 107, 30, 10.1016/j.jconrel.2004.06.024 Fonseca, 2002, Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity, J. Control. Release, 83, 273, 10.1016/S0168-3659(02)00212-2 Noori Koopaei, 2014, Docetaxel loaded PEG-PLGA nanoparticles: optimized drug loading, in-vitro Cytotoxicity and in-vivo antitumor effect, Iran. J. Pharm. Res. IJPR, 13, 819 Sharma, 2016, Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: a co-surfactant study, Asian J. Pharm. Sci., 11, 404, 10.1016/j.ajps.2015.09.004 Martins, 2014, Preparation and characterization of paclitaxel-loaded PLDLA microspheres, Mater. Res., 17, 650, 10.1590/S1516-14392014005000028 Radchenko, 2015, Structural basis for the blockade of MATE multidrug efflux pumps, Nat. Commun., 6, 7995, 10.1038/ncomms8995